Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age~2. Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2~3. Diagnosis of CML-CP associated with Bcr-Abl quantifiable by RQ-PCR (IS)~4. Patients must be an imatinib responder and achieved the following efficacy milestones as appropriate for the length of time on imatinib therapy as per protocol~5. CML-CP patients initiated on any dose of imatinib~6. Ability to provide written informed consent prior to any study related screening procedures being done~Exclusion Criteria:~1. Loss of CHR or cytogenetic response~2. Prior accelerated phase or blast phase CML~3. Previously documented T315I mutation~4. Presence of chromosomal abnormalities (trisomy 8) and/or clonal evolution other than Ph+.~5. Previous treatment with any other tyrosine kinase inhibitor except for imatinib.~6. Treatment with other investigational agents within 30 days of Day 1.~7. History of non-compliance to medical regimens or inability to grant consent.~8. Women who are pregnant, breast feeding, or of childbearing potential without a negative serum test at baseline. Male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nilotinib (Type: EXPERIMENTAL): Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).